UNCY Unicycive Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1766140 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-8.4%
TTM EPS YoY53.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-80.4%
ROA-60.1%
ROIC (approx.)-1,005.6%
Asset turnover—
Leverage & solvency
Liabilities / assets24.8%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.25M | $2.79M | $1.61M | $2.25M | $2.96M | $1.75M | $2.17M | $5.29M |
| SG&A expense | $6.59M | $7.35M | $6.83M | $4.97M | $4.38M | $5.21M | $5.82M | $3.97M |
| Operating income | -$8.84M | -$10.14M | -$8.44M | -$7.22M | -$7.34M | -$6.96M | -$7.99M | -$9.26M |
| Interest expense | — | — | — | $27,000 | $15,000 | $13,000 | $15,000 | $20,000 |
| Net income | -$7.00M | -$1.72M | -$12.82M | -$14.67M | -$6.01M | -$6.45M | $570,000 | -$21.52M |
| EBITDA | -$8.83M | -$10.13M | -$8.43M | -$7.21M | -$7.33M | -$6.96M | -$7.98M | -$9.25M |
| EPS (basic) | -0.25 | -0.06 | -0.54 | — | -0.33 | -0.52 | 0.04 | — |
| EPS (diluted) | -0.25 | -0.06 | -0.54 | — | -0.33 | -0.52 | -0.50 | — |
| Weighted avg. shares (diluted) | 28.27M | 26.92M | 23.91M | — | 18.07M | 12.30M | 12.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.97M | $44.19M | $37.37M | $29.20M | $42.70M | $22.33M | $19.77M | $26.14M |
| Short-term investments | $17.01M | $17.24M | $17.21M | $12.07M | — | — | — | — |
| Current assets | $69.16M | $71.32M | $63.55M | $48.96M | $50.29M | $29.53M | $27.35M | $30.95M |
| PP&E, net | $255,000 | $41,000 | $48,000 | $66,000 | $75,000 | $83,000 | $83,000 | $75,000 |
| Total assets | $69.93M | $72.03M | $64.41M | $49.13M | $50.61M | $30.00M | $27.95M | $31.67M |
| Current liabilities | $17.31M | $18.70M | $26.48M | $18.94M | $13.13M | $13.57M | $16.68M | $24.12M |
| Total liabilities | $17.31M | $18.76M | $26.70M | $18.94M | $13.13M | $13.57M | $16.68M | $24.24M |
| Shareholders' equity | $52.62M | $53.27M | $37.70M | $30.20M | $37.48M | $16.43M | $11.27M | $7.43M |
| Shares outstanding | 29.11M | 27.86M | 25.24M | 22.11M | 20.85M | 14.11M | 119.75M | 11.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.25M | -$7.60M | -$6.24M | -$8.03M | -$5.96M | -$8.42M | -$8.90M | -$6.55M |
| Capital expenditure | $221,000 | -$1,000 | $8,000 | $0 | $2,000 | $6,000 | $16,000 | $22,000 |
| Free cash flow | -$7.47M | -$7.60M | -$6.25M | -$8.03M | -$5.96M | -$8.43M | -$8.92M | -$6.57M |
| Investing cash flow | $63,000 | -$23,000 | -$5.16M | -$12.07M | -$2,000 | -$6,000 | -$16,000 | -$22,000 |
| Financing cash flow | $4.97M | $14.44M | $19.57M | $6.61M | $26.33M | $10.98M | $2.55M | $365,000 |
| Depreciation & amortization | $7,000 | $6,000 | $8,000 | $10,000 | $10,000 | $6,000 | $8,000 | $7,000 |
| Stock-based compensation | $1.80M | $2.88M | $754,000 | $777,000 | $729,000 | $571,000 | $563,000 | $582,000 |
| Dividends paid | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.